AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
AbbVie(ABBV) stock is priced at $225.08, giving the company a market capitalization of 397.24B. It carries a P/E multiple of 95.17 and pays a dividend yield of 3.0%.
As of 2026-02-27, AbbVie(ABBV) stock has fluctuated between $225.08 and $225.08. The current price stands at $225.08, placing the stock 0.0% above today's low and 0.0% off the high.
The AbbVie(ABBV)'s current trading volume is 1.83K, compared to an average daily volume of 6.31M.
During the past year, AbbVie(ABBV) stock moved between $164.39 at its lowest and $244.81 at its peak.
During the past year, AbbVie(ABBV) stock moved between $164.39 at its lowest and $244.81 at its peak.
ABBV News
If you are wondering whether AbbVie’s current share price lines up with its underlying worth, you are not alone. This article is built to help you unpack that q...
The latest announcement is out from AbbVie ( (ABBV) ). On February 24, 2026, AbbVie entered into an underwriting agreement with a syndicate of major banks to i...
The company is down slightly this year, but that may be a buying opportunity. A lot has changed for AbbVie (ABBV 0.98%) over the past five years. Notably, the...
Analyst ratings
64%
of 33 ratingsMore ABBV News
Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading today, for the April 10th expiration. At Stock Options Channel , our YieldBoost formula has...
RBC Capital analyst Trung Huynh initiated coverage of AbbVie (ABBV) with an Outperform rating and $260 price target The shares have underperformed on concerns A...
Key Points AbbVie has a collection of drugs that produce substantial cash flow. The company has steadily rewarded investors with dividend growth. 10 stocks w...
AbbVie (NYSE:ABBV) received FDA approval for its all oral, fixed duration VENCLEXTA and acalabrutinib regimen for previously untreated chronic lymphocytic leuke...
Abbvie (ABBV) announced an update on their ongoing clinical study. AbbVie (ABBV) has started a new Phase 1 trial called “A Phase 1 Pharmacokinetic Study in Hea...
AbbVie (ABBV) announced a new $380M investment to build two new active pharmaceutical ingredient manufacturing facilities at its current North Chicago, Illinois...
Abbvie (ABBV) announced an update on their ongoing clinical study. AbbVie (ABBV) is running a mid-stage trial to test new drugs for idiopathic pulmonary fibros...